Clinical trials
HER-2 Positive Breast Cancer clinical trials
Below are recruiting her-2 positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 262 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05878314Recruiting
Testing how hormones and tumor markers guide breast cancer treatment
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
TübingenAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT06686459Recruiting
AI-assisted single-session radiotherapy after breast-conserving surgery
This trial tests a new approach where all radiation is given in one session using AI guidance. It is for women who had breast-conserving surgery with lymph node removal and need radiation afterward.
GuangzhouAges 18–70 - NCT06298084RecruitingPhase 1/Phase 2
HER3-DXd for Advanced Breast Cancer After T-DXd
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
VillejuifAges 18 years+ - NCT05575804RecruitingPhase 1/Phase 2
GQ1001 plus pyrotinib for HER2-positive metastatic breast cancer
This trial tests a combination of two targeted drugs, GQ1001 and pyrotinib, for people with HER2-positive breast cancer that has spread to other parts of the body and has not responded to at least one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07358182Recruiting
Trastuzumab-rezetecan for breast cancer with HER2 protein
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT07748598Recruiting
Brain scan monitoring for HER2-positive breast cancer
This study is testing regular MRI brain scans to find any brain metastases early in people with HER2-positive breast cancer that has spread. It aims to see if early detection can help guide treatment and improve outcomes.
LiverpoolAges 16 years+ - NCT06106477Recruiting
Intermittent fasting for women with early breast cancer
This trial studies whether a 14-hour night fast and 10-hour eating window can improve inflammation markers and quality of life in women with HR+/HER2- early breast cancer. You would start the fasting routine within three months of beginning hormone therapy.
Milwaukee, WisconsinAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT07340541RecruitingPhase 2
Personalized cancer therapy trial based on tumor markers
This trial tests new treatments that are chosen based on specific markers in your tumor. Researchers want to see if these personalized therapies work better than standard options.
New Haven, ConnecticutAges 18 years+ - NCT07106632RecruitingPhase 3
Genomic test to guide chemotherapy in young women with breast cancer
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
BrusselsAges 35–45 - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Beverly Hills, CaliforniaAges 18 years+ - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT03827317Recruiting
Scan to see HER2 in breast cancer with a new tracer
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
LondonAges 18 years+ - NCT04069884Recruiting
Avoid extra lymph-node radiation for certain node-positive breast cancers
This trial tests a way to decide whether you can safely receive less radiation to lymph nodes after surgery for breast cancer that has spread to nearby nodes. If you qualify as “low risk,” the goal is to reduce radiation exposure while keeping cancer control safe.
Guangzhou, GuangdongAges 18–70 - NCT04383275RecruitingPhase 2
De-escalation trial for early HER2+ breast cancer
This Phase 2 study tests whether people with early-stage HER2-positive breast cancer may be treated with less intensive therapy, without losing effectiveness. You may be considered if your tumor is small, lymph nodes are negative, and your hormone (ER/PR) status and HER2 test results match the study groups.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04540692RecruitingPhase 3
Testing chemotherapy timing for certain HER2-negative breast cancers
This Phase 3 trial studies different ways of giving common chemotherapy drugs (anthracyclines and taxanes) for locally advanced breast cancer that is HER2-negative. It aims to see which order or “sequencing” may work better for people like you.
Cachoeiro de Itapemirim, Espírito SantoAges 18 years+ - NCT04636710Recruiting
Treatment approach study for stage III inflammatory breast cancer
This study looks at how to best plan local treatments (like surgery and/or radiation) for people with stage III inflammatory breast cancer. It may help doctors refine care plans for this aggressive subtype by studying how patients are treated and what outcomes they have.
Boston, MassachusettsAges 18 years+ - NCT04646759RecruitingPhase 3
Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Guangzhou, GuangdongAges 18–80 - NCT04683679RecruitingPhase 2
Radiation plus pembrolizumab and olaparib for certain breast cancers
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Basking Ridge, New JerseyAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+
Hear when a new HER-2 Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her-2 positive breast cancer?
- Yes. Clin2 currently lists 262 recruiting her-2 positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her-2 positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her-2 positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HR Positive/HER-2 Negative Breast Cancer
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- ER Positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.